子宮肌瘤治療市場－全球產業規模、佔有率、趨勢、機會、預測：按類型、治療方法、最終用戶、地區和競爭格局分類，2021-2031年

全球子宮肌瘤治療市場預計將從 2025 年的 51.5 億美元成長到 2031 年的 84.2 億美元，複合年成長率達到 8.54%。

本文重點在於良性子宮腫瘤—子宮肌瘤的治療和管理。市場成長的主要驅動力是人們對微創手術（例如子宮肌瘤栓塞術和腹腔鏡子宮肌瘤切除術）的需求不斷成長，這些手術能夠保留生育能力並縮短恢復時間。機器人手術系統的進一步發展和新藥療法的引入正在拓展治療選擇，並為傳統開放性手術提供有效的替代方案。然而，患者對替代療法的認知不足以及對傳統大型手術的過度依賴仍然是重要的障礙。 2024年的一項調查顯示，53%的女性最初提案子宮切除術，這限制了她們獲得現代治療方法的機會。

市場促進因素

市場擴張的主要驅動力是微創手術技術的顯著進步。這些技術從根本上改變了治療方式，為傳統的全子宮切除術提供了有效的保留子宮的替代方案。射頻消融術和子宮鏡肌瘤碎切術等手術能夠最大限度地縮短恢復時間並保留生育能力，患者對這類手術的興趣日益濃厚，推動了行業整合和對新型設備平台的投資，例如Hologic公司以3.5億美元收購Gynesonics公司。同時，新型GnRH拮抗劑的商業化也拓展了非手術治療的選擇。這些口服藥物療法能夠有效抑制月經並縮小子宮肌瘤的體積，解決了不仿單標示外手術或不願接受手術的女性所面臨的重大挑戰。像 Myfembree 這樣的療法銷售額年增了 32%，並且在全球子宮肌瘤患病率達到每 10 萬名女性 250.93 例的情況下，發揮著至關重要的作用。

市場挑戰

全球子宮肌瘤治療市場成長的主要限制因素是人們仍然過度依賴傳統大型手術，以及患者對替代療法的認知不足。這種資訊不對稱導致人們仍然傾向於選擇子宮切除術等根治性手術，使患者被排除在不孕症預防設備和長期管理療法的目標市場之外。因此，非手術治療方法的生產商在市場准入和實現預期銷售目標方面面臨著巨大的挑戰。介入放射學會2024年的一項調查凸顯了這項挑戰，該調查顯示，17%的女性錯誤地認為子宮切除術是唯一的治療方法，這直接阻礙了對子宮肌瘤栓塞術等微創治療方法的需求，也未能充分挖掘新興治療領域的市場潛力。

市場趨勢

一個值得關注的市場趨勢是影像導引非侵入性消融技術的進步。這些技術正在開闢一個全新的治療領域，使其與傳統的微創手術截然不同。例如，磁振造影（MRI）引導聚焦超音波（MRgFUS）等技術利用高強度聲波在無需皮膚切口的情況下破壞子宮肌瘤組織，提供了一種完全非侵入性的方法，既能保護子宮完整性，又無需術後恢復。對於尋求保留生育能力且不願承擔手術風險的患者而言，這無疑是個極具吸引力的選擇。這種非切口治療方法在臨床上迅速普及，可見一斑：到2025年，全球將有超過一百萬名患者因子宮肌瘤接受聚焦超音波治療。此外，保險公司為降低成本而提供的獎勵以及診所可用設備的廣泛普及，正推動著這項手術向門診和日間手術模式轉變，從而改變著醫療服務的提供方式。因此，MyoSure 和 Sonata 等系統在婦科門診機構中得到更廣泛的應用，從而促進了 Hologic 等公司的收入強勁成長。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：子宮肌瘤治療的全球市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依類型（漿膜下肌瘤、肌壁內肌瘤、黏膜下肌瘤、帶蒂肌瘤）
  • 治療方法（荷爾蒙療法、雄性激素、促性腺激素分泌釋放激素拮抗劑、子宮動脈栓塞術、肌瘤切除術、子宮切除術）
  • 依最終使用者（醫院/診所、門診手術中心、其他）分類
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美子宮肌瘤治療市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲子宮肌瘤治療市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區子宮肌瘤治療市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲子宮肌瘤治療市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲子宮肌瘤治療市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球子宮肌瘤治療市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Gynesonics Inc.
• Medtronic Plc.
• Boston Scientific Corporation
• Karl Storz Gmbh
• Pfizer Inc.
• Abbvie Inc.
• Richard Wolf GmbH
• CooperSurgical Inc.
• Olympus Corporation
• Myovant Sciences GmbH

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Uterine Fibroids Treatment Market is projected to grow from USD 5.15 billion in 2025 to USD 8.42 billion by 2031, achieving an 8.54% CAGR. As it centers on the therapeutic management of benign uterine tumors called leiomyomas. Market growth is primarily driven by the increasing demand for minimally invasive procedures that preserve fertility and reduce recovery times, such as uterine fibroid embolization and laparoscopic myomectomy. Further advancements in robotic surgical systems and the introduction of novel pharmacological therapies are expanding the treatment landscape, offering viable alternatives to traditional open surgeries. However, a significant barrier remains the lack of patient awareness regarding alternative therapies and a historical over-reliance on major surgery, evidenced by a 2024 survey where 53% of women were primarily offered a hysterectomy, limiting access to modern interventions.

Market Driver

Key drivers for market expansion include significant advancements in minimally invasive surgical techniques, which are fundamentally reshaping treatment by offering effective uterine-sparing alternatives to traditional hysterectomies. Patients' increasing preference for procedures like radiofrequency ablation and hysteroscopic morcellation, which minimize recovery time and preserve fertility, is fueling industry consolidation and investment in novel device platforms, as seen with Hologic's $350 million acquisition of Gynesonics. Concurrently, the commercialization of novel GnRH antagonists is broadening the therapeutic landscape for non-surgical management. These oral pharmacotherapies effectively control heavy menstrual bleeding and reduce fibroid volume, addressing a critical gap for women ineligible for or averse to surgery, with treatments like Myfembree showing a 32% year-over-year revenue increase, crucial amidst a rising global incidence rate of uterine fibroids reaching 250.93 per 100,000 women.

Market Challenge

A major impediment to the growth of the Global Uterine Fibroids Treatment Market is the persistent lack of patient awareness regarding alternative therapies, coupled with a historical over-reliance on major surgery. This information asymmetry leads to a continued preference for radical surgical interventions like hysterectomies, thereby removing patients from the addressable market for fertility-preserving devices and long-term management therapies. Consequently, manufacturers of non-surgical solutions face substantial difficulty in market penetration and achieving projected revenue targets. This challenge is underscored by a 2024 survey from the Society of Interventional Radiology, which indicated that 17% of women mistakenly believed a hysterectomy was the only available treatment, directly hindering demand for less invasive options like uterine fibroid embolization and underutilizing the market potential for emerging therapeutic segments.

Market Trends

Notable market trends include advancements in image-guided non-invasive ablation technologies, which are establishing a new therapeutic class distinct from traditional minimally invasive surgery. Technologies such as Magnetic Resonance-guided Focused Ultrasound (MRgFUS) use high-intensity sound waves to destroy fibroid tissue through intact skin, offering a completely non-invasive approach that preserves uterine integrity and eliminates surgical recovery time, appealing to patients seeking fertility-sparing options without surgical risks. The rapid clinical acceptance of this incision-less modality is highlighted by uterine fibroids being a leading indication among over one million patients treated with focused ultrasound technologies worldwide in 2025. Additionally, the migration of procedures to outpatient and ambulatory surgical settings is reshaping service delivery, driven by payer incentives for cost reduction and the availability of office-ready devices, leading to increased utilization of systems like MyoSure and Sonata in outpatient gynecological facilities, contributing to robust revenue growth for companies like Hologic.

Key Market Players

• Gynesonics Inc.
• Medtronic Plc.
• Boston Scientific Corporation
• Karl Storz Gmbh
• Pfizer Inc.
• Abbvie Inc.
• Richard Wolf GmbH
• CooperSurgical Inc.
• Olympus Corporation
• Myovant Sciences GmbH

Report Scope

In this report, the Global Uterine Fibroids Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Uterine Fibroids Treatment Market, By Type

• Subserosal Fibroids
• Intramural Fibroids
• Submucosal Fibroids
• Pedunculated Fibroids

Uterine Fibroids Treatment Market, By Treatment

• Hormone Therapy
• Androgens
• Gonadotropin-Releasing Hormone Antagonists
• Uterine Artery Embolization
• Myomectomy
• Hysterectomy

Uterine Fibroids Treatment Market, By End-User

• Hospitals & Clinics
• Ambulatory Surgical Centers
• Others

Uterine Fibroids Treatment Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Uterine Fibroids Treatment Market.

Available Customizations:

Global Uterine Fibroids Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Uterine Fibroids Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids, Pedunculated Fibroids)
  • 5.2.2. By Treatment (Hormone Therapy, Androgens, Gonadotropin-Releasing Hormone Antagonists, Uterine Artery Embolization, Myomectomy, Hysterectomy)
  • 5.2.3. By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Uterine Fibroids Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Treatment
  • 6.2.3. By End-User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Uterine Fibroids Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Treatment
      • 6.3.1.2.3. By End-User
  • 6.3.2. Canada Uterine Fibroids Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Treatment
      • 6.3.2.2.3. By End-User
  • 6.3.3. Mexico Uterine Fibroids Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Treatment
      • 6.3.3.2.3. By End-User

7. Europe Uterine Fibroids Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Treatment
  • 7.2.3. By End-User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Uterine Fibroids Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Treatment
      • 7.3.1.2.3. By End-User
  • 7.3.2. France Uterine Fibroids Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Treatment
      • 7.3.2.2.3. By End-User
  • 7.3.3. United Kingdom Uterine Fibroids Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Treatment
      • 7.3.3.2.3. By End-User
  • 7.3.4. Italy Uterine Fibroids Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Treatment
      • 7.3.4.2.3. By End-User
  • 7.3.5. Spain Uterine Fibroids Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Treatment
      • 7.3.5.2.3. By End-User

8. Asia Pacific Uterine Fibroids Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Treatment
  • 8.2.3. By End-User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Uterine Fibroids Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Treatment
      • 8.3.1.2.3. By End-User
  • 8.3.2. India Uterine Fibroids Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Treatment
      • 8.3.2.2.3. By End-User
  • 8.3.3. Japan Uterine Fibroids Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Treatment
      • 8.3.3.2.3. By End-User
  • 8.3.4. South Korea Uterine Fibroids Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Treatment
      • 8.3.4.2.3. By End-User
  • 8.3.5. Australia Uterine Fibroids Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Treatment
      • 8.3.5.2.3. By End-User

9. Middle East & Africa Uterine Fibroids Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Treatment
  • 9.2.3. By End-User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Uterine Fibroids Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Treatment
      • 9.3.1.2.3. By End-User
  • 9.3.2. UAE Uterine Fibroids Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Treatment
      • 9.3.2.2.3. By End-User
  • 9.3.3. South Africa Uterine Fibroids Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Treatment
      • 9.3.3.2.3. By End-User

10. South America Uterine Fibroids Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Treatment
  • 10.2.3. By End-User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Uterine Fibroids Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Treatment
      • 10.3.1.2.3. By End-User
  • 10.3.2. Colombia Uterine Fibroids Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Treatment
      • 10.3.2.2.3. By End-User
  • 10.3.3. Argentina Uterine Fibroids Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Treatment
      • 10.3.3.2.3. By End-User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Uterine Fibroids Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Gynesonics Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Medtronic Plc.
• 15.3. Boston Scientific Corporation
• 15.4. Karl Storz Gmbh
• 15.5. Pfizer Inc.
• 15.6. Abbvie Inc.
• 15.7. Richard Wolf GmbH
• 15.8. CooperSurgical Inc.
• 15.9. Olympus Corporation
• 15.10. Myovant Sciences GmbH

16. Strategic Recommendations

17. About Us & Disclaimer